| Document |
Document Title |
|
WO/2013/069339 |
Provided is a puncture pain alleviating external preparation which causes little pain and which can be easily used. The puncture pain alleviating external preparation of the present invention is to be applied in the vicinity of the site ...
|
|
WO/2013/067612 |
The present invention relates to the development of a pharmaceutical composition characterized by comprising triancinolone, bupivacaine and ethanol in the form of a suspension, the use thereof characterized by being for the preparation o...
|
|
WO/2013/046335 |
[Problem] In a non-aqueous patch containing lidocaine, the adhesive force of the preparation tends to lower with an increase in the content of lidocaine. To release an effective amount of lidocaine from a patch to the skin, it is a commo...
|
|
WO/2013/027184 |
This invention relates to a method of sedating, anaesthetising or euthanising an aquatic organism comprising the step of contacting said organism with linalool, a compositions, a body of water containing thereof and a method of transport...
|
|
WO/2013/026896 |
The invention relates to peptides comprising an amino acid sequence of or derived from a claudin protein for use as a pharmaceutical agent, in particular as an adjuvant or drug delivery-enhancing agent in pain therapy.
|
|
WO/2013/010210 |
The invention provides an oral composition comprising a pharmaceutically acceptable carrier, at least one antacid, an inorganic matrix comprising at least silicon dioxide and titanium dioxide, and an anaesthetic, wherein the composition ...
|
|
WO/2012/176668 |
A lidocaine-containing cataplasm comprising a backing layer and an adhesive agent (plaster) layer laminated on the surface of the backing layer, wherein the adhesive agent (plaster) layer contains at least one component selected from the...
|
|
WO/2012/153396 |
[Problem] Since a non-aqueous patch includes lidocaine without dissolution in a crystalline state, such non-aqueous patch has poor skin permeability, and therefore a high concentration of lidocaine is formulated. Lidocaine has been noted...
|
|
WO/2012/136356 |
The present invention relates to a compound of formula (1), a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as hypnotic agent or anesthetic agent.
|
|
WO/2012/136356 |
The present invention relates to a compound of formula (1), a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as hypnotic agent or anesthetic agent.
|
|
WO/2012/111380 |
The molecular structure of a metal salen complex erxhibiting a pharmacological effect has been clarified, and provided are a metal salen complex provided with such a molecular structure, as well as a derivative of the complex. A metal sa...
|
|
WO/2012/112969 |
The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a pati...
|
|
WO/2012/104782 |
The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the α7 subtype. The invention includes pyrrole derivatives, analogues, their prodrugs, their isotop...
|
|
WO/2012/101440 |
In one aspect, there is provided heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof for use as a local anaesthetic. In another aspect, there is provided a pharmaceutical composition comprising heptanone (e.g. 2-, 3- or 4-heptanone)...
|
|
WO/2012/088494 |
Compounds of Formula (I) are disclosed. The variables R1 R11 are described herein. Certain compounds of Formula (I) are partial agonists of the mu, delta, and kappa opioid receptors, and are useful for treating pain and opioid addiction,...
|
|
WO/2012/085683 |
The present invention relates to the use of spinosyns and spinosyn compositions as local anesthetics and antiarrhythmic agents. Advantageously, spinosyns may be used as local anesthetics and/or antiarrhythmic agents with little or no dis...
|
|
WO/2012/085648 |
The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I), and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined here...
|
|
WO/2012/085648 |
The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I), and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined here...
|
|
WO/2012/072781 |
The invention relates to pyrazole derivatives of formula (I) having pharmacological activity and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxi...
|
|
WO/2012/035421 |
The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The in...
|
|
WO/2012/035421 |
The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The in...
|
|
WO/2012/029097 |
Provided is a transdermal preparation such that lidocaine release properties can be controlled well with little skin irritation while sufficient adhesiveness is maintained when applied to the skin. The transdermal preparation has an adhe...
|
|
WO/2012/029070 |
The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel...
|
|
WO/2012/027811 |
The present invention relates to a new association of active principles with anesthetic and pre-anesthetic function, formulated into a composition that contains anesthetics and analgesic for surgical, pre-surgical procedures and the like...
|
|
WO/2012/031125 |
The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, ...
|
|
WO/2012/031125 |
The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, ...
|
|
WO/2012/027570 |
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
|
|
WO/2012/016980 |
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
|
|
WO/2012/016980 |
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
|
|
WO/2012/009823 |
The invention relates to technology for the veterinary domain, corresponding to a tranquilising/sedating pharmaceutical formulation, for reducing motor activity, comprising at least one neurosteroid with tranquilising activity and a tran...
|
|
WO/2012/004604 |
The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the ...
|
|
WO/2011/161439 |
This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher and / or an advantageous carrier system...
|
|
WO/2011/160267 |
Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof. The title compound is shown in formula (I), in which Y= C1-4 straight-chain carbon chain. The compound can release 2,6-diisopropylphenol rapid...
|
|
WO/2011/160268 |
Phosphoric acid ester compound of hydroxy acid substituted phenyl ester, synthesis method and medical use thereof. The title compound is shown in formula (I), in which Y= C1-4 straight-chain carbon chain and M1 and/or M2 = H, alkali meta...
|
|
WO/2011/161687 |
Disclosed herein is a process for the preparation of highly pure 2,6-diisopropyl phenol (Formula I), which comprises reacting p-hydroxy benzoic acid (Formula II) with an alkylating agent in presence of aq. mineral acid followed by basifi...
|
|
WO/2011/149412 |
The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations ar...
|
|
WO/2011/144248 |
The invention relates to a mixture of two active principles for removing atheromatous plaque, i.e. procaine of formula (I) and a pharmaceutically acceptable alkoxysilane or aryloxysilane and more particularly monomethyltrisilanol salicyl...
|
|
WO/2011/145993 |
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-α related activity level by more than ...
|
|
WO/2011/145660 |
The disclosed propofol-containing oil-in-water emulsion composition contains: propofol; an oily component that contains at least 30% by mass of medium-chain triglycerides, the fatty acid chains of which have a mean carbon number of 9.9 o...
|
|
WO/2011/127456 |
The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthet...
|
|
WO/2011/121345 |
The present invention relates to the use of an anesthetic agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anesthetic agent and an antimicrobial agent for the...
|
|
WO/2011/109341 |
A therapeutic composition having at least one botanical active ingredient, carvone, derived from plants such as mint Mentha sp., caraway Carum carvi or dill Anethum graveolens. Carvone is capable of anesthetizing teleost, elasmobranch, a...
|
|
WO/2011/088503 |
The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations compri...
|
|
WO/2011/090669 |
The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an α7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharm...
|
|
WO/2011/086146 |
The invention relates to a complex made of α-cyclodextrin and a halogenated ether, characterized by a content of the halogenated ether of at least 3 wt% of the total weight of the complex.
|
|
WO/2011/088333 |
Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application ...
|
|
WO/2011/079807 |
Dipropofol pyrophosphate dihydrogen ester and pharmaceutically acceptable salt, preparation process and application thereof. The ester (2) is prepared by phosphorylating propofol with P2O5 as phosphorylating reagent in anhydrous organic ...
|
|
WO/2011/074567 |
Disclosed is a transdermal preparation in which a basic anti-inflammatory agent is blended. The transdermal preparation is an adhesive patch for external use, which has excellent drug release properties without deteriorating the physical...
|
|
WO/2011/074695 |
A shivering suppressor which is capable of suppressing shivering occurring after dosing with an anesthetic, said anesthetic being remifentanil or a pharmaceutically acceptable salt thereof, and said shivering suppressor comprising naloxo...
|
|
WO/2011/074566 |
Disclosed is a felbinac-containing transdermal absorption preparation substantially free of felbinac solubilizer in the final formulation, but still having a high level of felbinac release. In particular is disclosed an adhesive patch wh...
|
